Our top pick for
ChemoCentryx, Inc is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 82 staff and has a trailing 12-month revenue of around USD$76.1 million.
Since the stock market crash in March caused by coronavirus, ChemoCentryx's share price has had significant positive movement.
Its last market close was USD$59.55, which is 17.93% up on its pre-crash value of USD$48.87 and 93.85% up on the lowest point reached during the March crash when the shares fell as low as USD$30.72.
If you had bought USD$1,000 worth of ChemoCentryx shares at the start of February 2020, those shares would have been worth USD$836.61 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,326.77.
|Latest market close||USD$59.55|
|52-week range||USD$7.5 - USD$65.43|
|50-day moving average||USD$53.7671|
|200-day moving average||USD$54.6741|
|Wall St. target price||USD$76.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.923|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||2.90%|
|1 month (2020-10-23)||1.28%|
|3 months (2020-08-25)||11.60%|
|6 months (2020-05-22)||-1.19%|
|1 year (2019-11-25)||638.83%|
|2 years (2018-11-23)||500.91%|
|3 years (2017-11-24)||755.60%|
|5 years (2015-11-25)||704.73%|
|Revenue TTM||USD$76.1 million|
|Gross profit TTM||USD$-34,148,000|
|Return on assets TTM||-5.1%|
|Return on equity TTM||-12.1%|
|Market capitalisation||USD$3.6 billion|
TTM: trailing 12 months
There are currently 5.5 million ChemoCentryx shares held short by investors – that's known as ChemoCentryx's "short interest". This figure is 4% up from 5.3 million last month.
There are a few different ways that this level of interest in shorting ChemoCentryx shares can be evaluated.
ChemoCentryx's "short interest ratio" (SIR) is the quantity of ChemoCentryx shares currently shorted divided by the average quantity of ChemoCentryx shares traded daily (recently around 681087.68656716). ChemoCentryx's SIR currently stands at 8.04. In other words for every 100,000 ChemoCentryx shares traded daily on the market, roughly 8040 shares are currently held short.
However ChemoCentryx's short interest can also be evaluated against the total number of ChemoCentryx shares, or, against the total number of tradable ChemoCentryx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChemoCentryx's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ChemoCentryx shares in existence, roughly 80 shares are currently held short) or 0.118% of the tradable shares (for every 100,000 tradable ChemoCentryx shares, roughly 118 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ChemoCentryx.
Find out more about how you can short ChemoCentryx stock.
We're not expecting ChemoCentryx to pay a dividend over the next 12 months.
Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $7.5 up to $65.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.6757. This would suggest that ChemoCentryx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.